pembrolizumab and lenvatinib


( Last Updated : November 10, 2021)
Generic Name:
pembrolizumab and lenvatinib
Project Status:
Pending
Therapeutic Area:
Advanced endometrial cancer
Manufacturer:
Merck Canada
Call for patient/clinician input open:
Brand Name:
Keytruda and Lenvima
Project Line:
Reimbursement Review
Project Number:
PC0271-000
Call for patient/clinician input closed:
Tumour Type:
Genitourinary

Details


Manufacturer Requested Reimbursement Criteria1:
Keytruda (pembrolizumab), as monotherapy, for the treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy, or in combination with lenvatinib for the treatment of adult patients with advanced endometrial cancer who have disease progression following prior platinum-based systemic therapy in any setting and are not candidates for curative surgery or radiation.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Keytruda for Adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) endometrial cancer whose tumours have progressed following prior therapy and who have no satisfactory alternative treatment options, as monotherapy. Keytruda, in combination with lenvatinib, is indicated for the treatment of adult patients with advanced endometrial carcinoma who have disease progression following prior platinum-based systemic therapy in any setting and are not candidates for curative surgery or radiation.
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.